DVA Quote, Financials, Valuation and Earnings

CVS Health has a net margin of 7.87% compared to DaVita's net margin of 1.68%. DaVita's return on equity of 38.64% beat CVS Health's return on equity of 6.12%.

DaVita has a consensus price target of $163.26, signalling upside risk potential of 15.69%. On the other hand CVS Health has an analysts' consensus of $71.70 which suggests that it could grow by 9.05%. Given that DaVita has higher upside potential than CVS Health, analysts believe DaVita is more attractive than CVS Health.

DaVita has a beta of 0.990, which suggesting that the stock is 1.011% less volatile than S&P 500. In comparison CVS Health has a beta of 0.537, suggesting its less volatile than the S&P 500 by 46.292%.

DaVita has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CVS Health offers a yield of 4.05% to investors and pays a quarterly dividend of $0.67 per share. DaVita pays -- of its earnings as a dividend. CVS Health pays out 73.1% of its earnings as a dividend. CVS Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

DaVita quarterly revenues are $3.3B, which are smaller than CVS Health quarterly revenues of $97.7B. DaVita's net income of $259.3M is lower than CVS Health's net income of $1.6B. Notably, DaVita's price-to-earnings ratio is 13.14x while CVS Health's PE ratio is 17.96x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DaVita is 0.96x versus 0.22x for CVS Health. Usually stocks with elevated PS ratios are considered overvalued.

Encompass Health has a net margin of 7.87% compared to DaVita's net margin of 8.61%. DaVita's return on equity of 38.64% beat Encompass Health's return on equity of 17.79%.

DaVita has a consensus price target of $163.26, signalling upside risk potential of 15.69%. On the other hand Encompass Health has an analysts' consensus of $117.25 which suggests that it could grow by 25.16%. Given that Encompass Health has higher upside potential than DaVita, analysts believe Encompass Health is more attractive than DaVita.

DaVita has a beta of 0.990, which suggesting that the stock is 1.011% less volatile than S&P 500. In comparison Encompass Health has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.121%.

DaVita has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Encompass Health offers a yield of 0.68% to investors and pays a quarterly dividend of $0.17 per share. DaVita pays -- of its earnings as a dividend. Encompass Health pays out 13.78% of its earnings as a dividend. Encompass Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

DaVita quarterly revenues are $3.3B, which are larger than Encompass Health quarterly revenues of $1.4B. DaVita's net income of $259.3M is higher than Encompass Health's net income of $120.9M. Notably, DaVita's price-to-earnings ratio is 13.14x while Encompass Health's PE ratio is 21.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DaVita is 0.96x versus 1.78x for Encompass Health. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of 7.87% compared to DaVita's net margin of 26.88%. DaVita's return on equity of 38.64% beat ResMed's return on equity of 25.56%.

DaVita has a consensus price target of $163.26, signalling upside risk potential of 15.69%. On the other hand ResMed has an analysts' consensus of $269.38 which suggests that it could grow by 22.6%. Given that ResMed has higher upside potential than DaVita, analysts believe ResMed is more attractive than DaVita.

DaVita has a beta of 0.990, which suggesting that the stock is 1.011% less volatile than S&P 500. In comparison ResMed has a beta of 0.738, suggesting its less volatile than the S&P 500 by 26.22%.

DaVita has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed offers a yield of 0.94% to investors and pays a quarterly dividend of $0.53 per share. DaVita pays -- of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

DaVita quarterly revenues are $3.3B, which are larger than ResMed quarterly revenues of $1.3B. DaVita's net income of $259.3M is lower than ResMed's net income of $344.6M. Notably, DaVita's price-to-earnings ratio is 13.14x while ResMed's PE ratio is 25.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DaVita is 0.96x versus 6.58x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.

US Physical Therapy has a net margin of 7.87% compared to DaVita's net margin of 4.12%. DaVita's return on equity of 38.64% beat US Physical Therapy's return on equity of 3.86%.

DaVita has a consensus price target of $163.26, signalling upside risk potential of 15.69%. On the other hand US Physical Therapy has an analysts' consensus of $110.00 which suggests that it could grow by 42.95%. Given that US Physical Therapy has higher upside potential than DaVita, analysts believe US Physical Therapy is more attractive than DaVita.

DaVita has a beta of 0.990, which suggesting that the stock is 1.011% less volatile than S&P 500. In comparison US Physical Therapy has a beta of 1.507, suggesting its more volatile than the S&P 500 by 50.722%.

DaVita has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. US Physical Therapy offers a yield of 2.29% to investors and pays a quarterly dividend of $0.45 per share. DaVita pays -- of its earnings as a dividend. US Physical Therapy pays out 100.3% of its earnings as a dividend.

DaVita quarterly revenues are $3.3B, which are larger than US Physical Therapy quarterly revenues of $180.4M. DaVita's net income of $259.3M is higher than US Physical Therapy's net income of $7.4M. Notably, DaVita's price-to-earnings ratio is 13.14x while US Physical Therapy's PE ratio is 41.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DaVita is 0.96x versus 1.73x for US Physical Therapy. Usually stocks with elevated PS ratios are considered overvalued.